This was the stock's fourth consecutive day of losses.

This was the stock's third consecutive day of losses.

IQVIA (NYSE:IQV – Get Free Report) had its price target lifted by Morgan Stanley from $245.00 to $250.00 in a report released on Tuesday,Benzinga reports. The brokerage presently has an “overweight” ...

Clinical research company IQVIA (NYSE: IQV) in Q4 CY2024, with sales up 2.3% year on year to $3.96 billion. On the other hand ...

Q4 2024 Earnings Call Transcript February 6, 2025 IQVIA Holdings Inc. beats earnings expectations. Reported EPS is $3.12, ...

In a report released today, Tejas Savant from Morgan Stanley maintained a Buy rating on IQVIA Holdings (IQV – Research Report), with a price ...

Retirement Systems of Alabama cut its stake in shares of IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 1.3% during the 4th ...

Feb 6 (Reuters) - Contract research firm IQVIA Holdings (IQV.N), opens new tab beat Wall Street estimates for fourth-quarter profit and revenue on Thursday, helped by the demand for its healthcare ...

Evercore ISI analyst Elizabeth Anderson CFA maintained a Buy rating on IQVIA Holdings (IQV – Research Report) on February 7 and set a price ...

According to IQVIA, sales data for the 12-month period ending December 2024, the Xalatan Ophthalmic Solution achieved annual ...

Clinical research company IQVIA (NYSE: IQV) will be announcing earnings results tomorrow before market hours. Here’s what to ...

Clinical research company IQVIA (NYSE: IQV) beat Wall Street’s revenue expectations in Q4 CY2024, with sales up 2.3% year on year to $3.96 billion. On the other hand, the company’s full-year ...